Document:

Exhibit 10.1

NOTE AND WARRANT PURCHASE AGREEMENT

          This NOTE AND
WARRANT PURCHASE AGREEMENT (this “Agreement”) is made as
of April 15, 2005 by and among Large Scale Biology Corporation, a Delaware
corporation (the “Company”), Predictive Diagnostics,
Inc., a Delaware corporation and a wholly-owned subsidiary of the Company
(“PDI”), and Kevin J. Ryan
(“Investor”).

RECITALS

          A.          The Company is currently in need of funds to help finance its operations until the closing of its next round of equity financing.

          B.          The Company has developed certain intellectual property related to its proprietary approach to early diagnosis of life-threatening diseases (“Intellectual Property”), and has formed a wholly-owned subsidiary, PDI, to commercialize such developments.

          C.          The Investor is willing to advance funds to the Company, some of which will fund PDI’s operations, in exchange for the issuance to him of (i) a Secured Promissory Note evidencing the Company’s obligation to repay the Investor’s loan of the advanced funds secured by a first priority security interest in the Intellectual Property; and (ii) a Warrant to purchase certain shares of capital stock of the Company or PDI, all as provided in this Agreement.

          NOW THEREFORE, the parties hereby agree as follows:

          1.     PURCHASE AND SALE OF NOTE AND WARRANT.

                         1.1     Note Purchase.  Subject to the terms and conditions of this Agreement, the Company agrees to sell to Investor, and Investor agrees to purchase from the Company, a Secured Promissory Note in the form attached to this Agreement as Exhibit A (the “Note”) in the principal amount of $3,000,000.00.  The performance of the Company of its obligations under the Note is secured by a Security Agreement in the form attached hereto as Exhibit B (the “Security Agreement”) and a Patent Security Agreement in the form attached hereto as Exhibit C (the “Patent Security Agreement” and together with the Security Agreement, the “Security Agreements”) each
entered into by the Company and the Investor as of even date herewith.

                         1.2     Warrant Issuance.  Subject to the terms and conditions of this Agreement, the Company further agrees to sell and issue to Investor a warrant to purchase shares of the Company’s capital stock (“LSBC Stock”) or shares of PDI’s capital stock (“PDI Stock”, and collectively with LSBC Stock, “Warrant Stock”) in the form attached hereto as Exhibit D (the “Warrant”).

          2.     CLOSING.  The purchase and sale of the Note and the Warrant will take place at the offices of the Company, 3333 Vaca Valley Parkway, Vacaville, California, on April 15, 2005 at 11:00 a.m. Pacific time, or at such other time and place as the Company and the Investor mutually agree upon (which time and place are referred to as the “Closing”).  At the Closing, Investor will deliver to the Company payment in full for the Note and the Warrant in the amount of $3,000,000, which Investor agrees to purchase at the Closing by wire transfer of funds to the Company.  At the Closing, the Company will deliver to the Investor a duly executed Note and a duly executed Warrant.

          3.     REPRESENTATIONS AND WARRANTIES OF THE COMPANY.  The Company hereby represents and Warrant to Investor that the statements in the following paragraphs of this Section 3 are all true and complete as of immediately prior to the Closing:

                         3.1     Organization, Good Standing and Qualification.  The Company has been duly incorporated and organized, and is validly existing in good standing, under the laws of the State of Delaware.  The Company has the corporate power and authority to own and operate its properties and assets and to carry on its business as currently conducted and as presently proposed to be conducted.

                         3.2     Due Authorization.  All corporate action on the part of the Company’s directors and shareholders necessary for the authorization, execution, delivery of, and the performance of all obligations of the Company under, this Agreement, the Note, the Warrant and the Security Agreements has been taken or will be taken prior to the Closing, and this Agreement constitutes, and the Note, the Warrant and the Security Agreements, when executed and delivered, will constitute, valid and legally binding obligations of the Company, enforceable in accordance with their respective terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditor’s rights
generally and (ii) the effect of rules of law governing the availability of equitable remedies.

                         3.3     Corporate Power.  The Company has the corporate power and authority to execute and deliver this Agreement, the Note, the Warrant and the Security Agreements to be purchased by the Investor hereunder, to issue the Note and the Warrant and to carry out and perform all its obligations under this Agreement, the Note, the Warrant and the Security Agreements.

                         3.4     Valid Issuance.

                                                  (a)     The Warrant and the Warrant Stock (the “Securities”), when issued, sold and delivered in accordance with the terms of this Agreement and the Warrant for the consideration provided for herein and therein, will be duly and validly issued, fully paid and nonassessable.

                                                  (b)     Based in part on the representations made by the Investor in Section 4 hereof, the offer and sale of the Securities solely to the Investor in accordance with this Agreement are exempt from the registration and prospectus delivery requirements of the U.S. Securities Act of 1933, as amended (the “1933 Act”) and the securities registration and qualification requirements of the currently effective provisions of the securities laws of the state in which the Investor is resident.

          4.     REPRESENTATIONS, WARRANTIES AND CERTAIN AGREEMENTS OF INVESTOR.  Investor hereby represents and warrants to, and agrees with, the Company, that:

                         4.1     Authorization.  This Agreement constitutes Investor’s valid and legally binding obligation, enforceable in accordance with its terms except as may be limited by  (i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and (ii) the effect of rules of law governing the availability of equitable remedies.  Investor represents that Investor has full power and authority to enter into this Agreement.

                         4.2     Purchase for Own Account.  The Securities will be acquired for investment for Investor’s own account, not as a nominee or agent, and not with a view to the public resale or distribution thereof within the meaning of the 1933 Act, and Investor has no present intention of selling, granting any participation in, or otherwise distributing the same.

                         4.3     Disclosure of Information.  Investor has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the Securities.  Investor further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Investor or to which Investor had access.  The foregoing, however, does not in any way limit or modify the representations and warranties made by the Company in Section 3.

                         4.4     Investment Experience.  Investor understands that the purchase of the Securities involves substantial risk.  Investor (i) has experience as an investor in securities of companies in the development stage and acknowledges that Investor is able to fend for himself, can bear the economic risk of Investor’s investment in the Securities and has such knowledge and experience in financial or business matters that Investor is capable of evaluating the merits and risks of this investment in the Securities and protecting his own interests in connection with this investment and/or (ii) has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables
Investor to be aware of the character, business acumen and financial circumstances of such persons.

                         4.5     Accredited Investor Status.  Investor is an “accredited investor” within the meaning of Regulation D promulgated under the 1933 Act.

                         4.6     Restricted Securities.  Investor understands that the Securities are characterized as “restricted securities” under the 1933 Act and Rule 144 promulgated thereunder inasmuch as they are being acquired from the Company in a transaction not involving a public offering, and that under the 1933 Act and applicable regulations thereunder such securities may be resold without registration under the 1933 Act only in certain limited circumstances.  In this connection, Investor is familiar with Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the 1933 Act.  Investor understands that the Company is under no obligation to register any of the securities sold hereunder.  Investor understands that no
public market now exists for any of the Securities and that it is uncertain whether a public market will ever exist for the Securities.

                         4.7     No Solicitation.  At no time was the Investor presented with or solicited by any publicly issued or circulated newspaper, mail, radio, television or other form of general advertising or solicitation in connection with the offer, sale and purchase of the Securities.

                         4.8     Further Limitations on Disposition.  Without in any way limiting the representations set forth above, Investor further agrees not to make any disposition of all or any portion of the Securities unless and until:

                                                  (a)     there is then in effect a registration statement under the 1933 Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or

                                                  (b)     Investor shall have notified the Company of the proposed disposition, and shall have furnished the Company with a statement of the circumstances surrounding the proposed disposition, and, at the expense of Investor or his transferee, with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such securities under the 1933 Act.

Notwithstanding the provisions of paragraphs (a) and (b) above, no such registration statement or opinion of counsel shall be required:  (i) for any transfer of any Securities in compliance with Rule 144 or Rule 144A; (ii) for any transfer of any Securities by an Investor that is a partnership or a corporation to (A) a partner of such partnership or shareholder of such corporation, (B) a controlled affiliate of such partnership or corporation, (C) a retired partner of such partnership who retires after the date hereof, (D) the estate of any such partner or shareholder; or (iii) for the transfer by gift, will or in testate succession by any Investor to his or her spouse or lineal descendants or ancestors or any trust for any of the foregoing; provided that in each of the foregoing cases the transferee agrees in writing to be subject to the terms of this Section 4 to the same extent as if the transferee
were an original Investor hereunder.

                         4.9     Legends.  Investor understands and agrees that the certificates evidencing the Securities will bear legends substantially similar to those set forth below in addition to any other legend that may be required by applicable law, by the Company’s Certificate of Incorporation or Bylaws, or by any agreement between the Company and Investor: 

                                                  (a)     THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES.  THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.  INVESTOR SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.  THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL
IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

                                                  (b)     Any legend required by state securities laws.

The legend set forth in (a) above shall be removed by the Company from any certificate evidencing the Securities upon delivery to the Company of an opinion of counsel, reasonably satisfactory to the Company, that a registration statement under the 1933 Act is at that time in effect with respect to the legended security or that such security can be freely transferred in a public sale (other than pursuant to Rule 144 or Rule 145 under the 1933 Act) without such a registration statement being in effect and that such transfer will not jeopardize the exemption or exemptions from registration pursuant to which the Company issued the Securities.

                         4.10     Piggy-Back Registrations.  If at any time following the issuance, if any, of shares of LSBC Stock or PDI Stock, as the case shall be, the Company or PDI shall determine to prepare and file with the Securities and Exchange Commission a registration statement relating to an offering for its own account or the account of others under the 1933 Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the 1933 Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with the stock option or other employee benefit plans, then the Company or PDI shall send to Investor a written notice of such
determination and, if within fifteen days after the date of such notice, Investor shall so request in writing, the Company or PDI shall include in such registration statement all or any part of the LSBC Stock issued to Investor upon exercise of the Warrant that Investor requests to be registered, subject to customary underwriter cutbacks applicable to all Investors of registration rights and the other terms and conditions of such offering, including without limitation the execution by the participating Investors of an underwriting agreement in the form to be used in connection with such offering.

                         4.11     Lockup Agreement.  Investor hereby agrees that it shall not, to the extent requested by the Company or PDI or an underwriter of securities of the Company or PDI, as applicable, sell or otherwise transfer or dispose of any shares of LSBC Stock or PDI Stock then owned by such Holder (other than to donees or partners of the Holder who agree to be similarly bound) for up to one hundred eighty (180) days following the effective date of any registration statement of the Company or PDI filed under the Securities Act.  The stock certificate(s) representing the LSBC Stock or PDI Stock, as applicable, will bear appropriate legends reflecting the restrictions of this Section 4.11.

          5.     CONDITIONS TO CLOSING.

                         5.1     Conditions to Investor’ Obligations.  The obligations of the Investor under Section 2 of this Agreement are subject to the fulfillment or waiver, on or before the Closing, of each of the following conditions:

                                                   (a)     Each of the representations and warranties of the Company contained in Section 3 shall be true and correct on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the date of the Closing; and

                                                   (b)     the Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing and shall have obtained all approvals, consents and qualifications necessary to complete the purchase and sale described herein.

                         5.2     Condition to Company’s Obligations.  The obligations of the Company to Investor under this Agreement are subject to the fulfillment or waiver on or before the Closing of the following condition by Investor:

                                                   (a)     Each of the representations and warranties of Investor contained in Section 4 shall be true and correct on the date of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing; and

                                                   (b)     Investor shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing and shall have obtained all approvals, consents and qualifications necessary to complete the purchase and sale described herein.

          6.     GENERAL PROVISIONS.

                         6.1     Survival of Warranties.  The representations, warranties and covenants of the Company and the Investor contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of any of the Investor or the Company, as the case may be.

                         6.2     Successors and Assigns.  The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties.

                         6.3     Governing Law.  This Agreement shall be governed by and construed under the internal laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California, without reference to principles of conflict of laws or choice of laws.

                         6.4     Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

                         6.5     Headings.  The headings and captions used in this Agreement are used only for convenience and are not to be considered in construing or interpreting this Agreement.  All references in this Agreement to sections, paragraphs, exhibits and schedules shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits and schedules attached hereto, all of which exhibits and schedules are incorporated herein by this reference.

                         6.6     Notices.  Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given (i) at the time of personal delivery, if delivery is in person; (ii) one (1) business day after deposit with an express overnight courier for United States deliveries, or two (2) business days after such deposit for deliveries outside of the United States, with proof of delivery from the courier requested; or (iii) three (3) business days after deposit in the United States mail by certified mail (return receipt requested) for United States deliveries when addressed to the Investor to be notified at the address indicated on the signature page hereof, or, in the case of the Company, at 3333 Vaca
Valley Parkway, Vacaville, CA 95688, or at such other address as any party may designate by giving ten (10) days’ advance written notice to all other parties.  

                         6.7     No Finder’s Fees.  Each party represents that it neither is nor will be obligated for any finder’s or broker’s fee or commission in connection with this transaction.  Each Investor agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finders’ or broker’s fee (and any asserted liability) for which the Investor or any of its officers, partners, employees, or representatives is responsible.  The Company agrees to indemnify and hold harmless each Investor from any liability for any commission or compensation in the nature of a finder’s or broker’s fee (and any asserted liability) for which the Company or any of its officers, employees or
representatives is responsible.

                         6.8     Amendments and Waivers.  Any term of this Agreement the Note and the Warrant may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investor.

                         6.9     Severability.  If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision(s) shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision(s) were so excluded and shall be enforceable in accordance with its terms.

                         6.10     Entire Agreement.  This Agreement, together with all exhibits and schedules hereto, the Note, the Warrant and the Security Agreements entered into pursuant hereto, constitutes the entire agreement and understanding of the parties with respect to the subject matter hereof and supersedes any and all prior negotiations, correspondence, agreements, understandings duties or obligations between the parties with respect to the subject matter hereof.

                         6.11     Further Assurances.  From and after the date of this Agreement, upon the request of any Investor or the Company, the Company and the Investor shall execute and deliver such instruments, documents or other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

	
  
LARGE SCALE BIOLOGY   CORPORATION
  	
  
 
  	
  
KEVIN J. RYAN
  
	
  
 
  	
  
 
  	
  
 
  	
  
 
  
	
  
By:
  	
  
/s/ RONALD J. ARTALE
  	
  
 
  	
  
/s/ KEVIN J. RYAN
  
	
   
  	
  

  	
  
 
  	
  

  
	
  
Name:
  	
  
Ronald J. Artale
  	
  
 
  	
  
 
  
	
  
Title:
  	
  
Chief Operating Officer, Chief Financial Officer and   Senior Vice President
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
 
  	
  
 
  
	
  
By:
  	
  
/s/ MICHAEL D. CENTRON
  	
  
 
  	
  
 
  
	
  
 
  	
  

  	
  
 
  	
  
 
  
	
  Name:
  	
  
Michael D. Centron
  	
  
 
  	
  
 
  
	
  
Title:
  	
  
Vice President, Finance and Administration
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
 
  	
  
 
  
	
  
PREDICTIVE DIAGNOSTICS, INC.
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
 
  	
  
 
  
	
  
By:
  	
  
/s/ JOHN S. RAKITAN
  	
  
 
  	
  
 
  
	
   
  	
  

  	
  
 
  	
  
 
  
	
  
Name:
  	
  
John S. Rakitan
  	
  
 
  	
  
 
  
	
  
Title:
  	
  
Senior Vice President, Chief Financial Officer and   Secretary
  	
  
 
  	
  
 
  

	
  
Attachments:
  
	
  
 
  
	
  
Exhibit A-
  	
  
Form of Note
  
	
  
Exhibit B-
  	
  
Security Agreement
  
	
  Exhibit D-
  	
  Patent Security Agreement
  
	
  Exhibit D-
  	
  Form of Warrant
  

SIGNATURE PAGE TO NOTE AND WARRANT PURCHASE AGREEMENTExhibit 10.2

SECURED PROMISSORY NOTE

Vacaville, California

	
  
$3,000,000.00
  	
  
April 15, 2005
  

          1.          Obligation. 
The undersigned, Large Scale Biology Corporation, a Delaware corporation
(“Borrower”) hereby promises to pay to the order of
Kevin J. Ryan, (“Lender” or “Holder”) on or
before April 17, 2006 (“Maturity Date”), as set forth
herein, at Lender’s principal place of business at 3333 Vaca Valley
Parkway, Vacaville, CA 95688, or at such other place as Holder may direct, the
principal sum of Three Million Dollars ($3,000,000.00), together with interest as
set forth in this Note, until the unpaid principal and all interest accrued
thereon are paid.  Interest will accrue on the unpaid principal, at a rate
equal to the greater of (a) the Prime Rate set from time to time by Bank of
America NT & SA plus two percent (2%) per annum or (b) Seven and One-Quarter
percent (7.25%) per annum, computed on the basis of a 360 day year and 30 day
months (“Interest Rate”).  The principal amount of
this Note will be payable in a lump sum on the Maturity Date.  Borrower
will pay Interest accruing under this Note each month, on the 15th
day of the month, beginning May 15, 2005.  The Interest Rate will float and
will be determined on a daily basis.  

          In connection with each Financing (as defined below) that closes following the date of this Note, the Holder may elect in writing to accelerate up to the lesser of (i) $1,500,000 of the unpaid principal balance or (ii) the unpaid principal balance then outstanding under this Note, at which time such amount will become immediately due and payable on the later to occur of the date of such closing or thirty (30) days following such written election.  For purposes of this paragraph, a “Financing” means the sale of shares of capital stock (but not issuances of options or warrants to acquire such capital stock) in one transaction or series of related transactions undertaken by the Borrower primarily for capital raising purposes and occurring on or before the Maturity Date for an aggregate purchase price paid to the Borrower of no less than Four Million Dollars
($4,000,000.00).

          As used herein, the term “Holder” shall initially mean Lender, and shall subsequently mean each person or entity to whom this Note is duly assigned.

          2.          Prepayment.  Prepayment of unpaid principal and/or interest due under this Note may be made by Borrower or (without any obligation on the part thereof) by Predictive Diagnostics, Inc., a subsidiary of the Borrower, at any time without penalty.  Unless otherwise agreed in writing by Holder, all payments will be made in lawful tender of the United States and will be applied (a) first, to the payment of accrued interest, and (b) second (to the extent that the amount of such prepayment exceeds the amount of all such accrued interest), to the payment of principal.  

          3.          Security.  The Company’s obligations under this Note are secured by a security interest in certain collateral granted by the Company to the original holder of this Note pursuant to the terms of a certain Security Agreement attached hereto as Exhibit A, which agreement is incorporated herein by reference.

          4.          Default; Acceleration of Obligation.  Borrower will be deemed to be in default under this Note and the outstanding unpaid principal balance of this Note, together with all interest accrued thereon, will immediately become due and payable in full, without the need for any further action on the part of Holder, upon the occurrence of any of the following events (each an “Event of Default”):  (a) upon Borrower’s failure to make any payment when due under this Note;  (b) upon the filing by or against Borrower of any voluntary or involuntary petition in bankruptcy or any petition for relief under the federal bankruptcy code or any other state or federal law for the relief of debtors; provided, however, with respect to an involuntary petition in bankruptcy, such
petition has not been dismissed within sixty (60) days after the filing of such petition; or (c) upon the execution by Borrower of an assignment for the benefit of creditors or the appointment of a receiver, custodian, trustee or similar party to take possession of Borrower’s assets or property.

          5.          Remedies On Default; Acceleration.  Upon any Event of Default, Holder will have, in addition to its rights and remedies under this Note, full recourse against any real, personal, tangible or intangible assets of Borrower, and may pursue any legal or equitable remedies that are available to Holder, and may declare the entire unpaid principal amount of this Note and all unpaid accrued interest under this Note to be immediately due and payable in full.

          6.          Waiver and Amendment.  Any provision of this Note may be amended or modified only by a writing signed by both Borrower and Holder.  Except as provided below with respect to waivers by Borrower, no waiver or consent with respect to this Note will be binding or effective unless it is set forth in writing and signed by the party against whom such waiver is asserted.  No course of dealing between Borrower and Holder will operate as a waiver or modification of any party’s rights or obligations under this Note.  No delay or failure on the part of either party in exercising any right or remedy under this Note will operate as a waiver of such right or any other right.  A waiver given on one occasion will not be construed as a bar to, or as a waiver of, any right or remedy on any future
occasion.

          7.          Waivers of Borrower.  Borrower hereby waives presentment, notice of non-payment, notice of dishonor, protest, demand and diligence.  This Note may be amended only by a writing executed by Borrower and Holder.  

          8.          Governing Law.  This Note will be governed by and construed in accordance with the internal laws of the State of California as applied to agreements between residents thereof to be performed entirely within such State, without reference to that body of law relating to conflict of laws or choice of law. 

          9.          Severability; Headings.  The invalidity or unenforceability of any term or provision of this Note will not affect the validity or enforceability of any other term or provision hereof.  The headings in this Note are for convenience of reference only and will not alter or otherwise affect the meaning of this Note.

          10.          Jurisdiction; Venue.  Borrower, by its execution of this Note, hereby irrevocably submits to the in personam jurisdiction of the state courts of the State of California for the purpose of any suit, action or other proceeding arising out of or based upon this Note.

          11.          Attorneys’ Fees.  If suit is brought for collection of this Note, Borrower agrees to pay all reasonable expenses, including attorneys’ fees, incurred by Holder in connection therewith whether or not such suit is prosecuted to judgment.

          12.          Assignment.  This Note is freely transferable and assignable by Holder, provided that such transfer is made in compliance with all applicable state and federal securities laws.  Any reference to Holder herein will be deemed to refer to any subsequent transferee of this Note at such time as such transferee holds this Note.   This Note may not be assigned or delegated by Borrower, whether by voluntary assignment or transfer, operation of law, merger or otherwise.  

          IN WITNESS WHEREOF, Borrower has executed this Note as of the date and year first above written.

	
   
  	
  
 
  	
  
 
  	
  
BORROWER:
  
	
  
 
  	
  
 
  	
  
 
  	
  
 
  	
  
 
  
	
  
 
  	
  
 
  	
  
 
  	
  
LARGE SCALE BIOLOGY   CORPORATION
  
	
  
 Agreed to and Acknowledged by: 

  	
  
 
  	
  
a Delaware corporation
  
	
  

  	
  
 
  	
  
 
  	
  
 
  
	
   LENDER: 

  	
  
 
  	 	 
	
   
  	
  
 
  	 By:
	 /s/ RONALD J. ARTALE

	 By:
	 /s/ KEVIN J. RYAN
	 	  
	

   
	 	
	 	 Name:
	 Ronald J. Artale

	Name:
	Kevin J. Ryan
	 	 Title:
	 Chief Operating Officer, Chief Financial Officer and Senior Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}]]